Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Enhancing PNH Care: Collaborative Decision-Making and Improving Patient Experience : Episode 3

Navigating Treatment Options: Understanding Risks and Benefits

January 9, 2025
By David Dingli, MD, PhD
Brandi Lewis
Opinion
Video

Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.

EP: 1.Recognizing PNH and Initial Challenges

EP: 2.Empowering Patients in Treatment Planning

Now Viewing

EP: 3.Navigating Treatment Options: Understanding Risks and Benefits

EP: 4.Decoding Symptoms: When Fatigue Speaks Volumes

EP: 5.Starting Treatment: Insights and Initial Experiences

EP: 6.Living With PNH: Long-Term Management and Caregiver Support

EP: 7.Patient Voices: Shaping the Future of PNH Care

EP: 8.Closing Reflection: A Journey of Understanding and Resilience

Video content above is prompted by the following:

  • How do you help patients weigh the risks and benefits of different treatment options?
  • What tools or techniques do you use to ensure patients and caregivers fully understand their choices?

This program was made possible with support from Novartis Pharmaceuticals.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Advertisement

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff
November 5th 2022
Article

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

ONCOLOGY Staff
September 18th 2022
Article

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.


1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
April 15th 2025
Podcast

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.


Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

ONCOLOGY Staff
July 16th 2022
Article

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.


Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

ONCOLOGY Staff
June 20th 2022
Article

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.

Related Content
Advertisement

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff
November 5th 2022
Article

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

ONCOLOGY Staff
September 18th 2022
Article

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.


1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
April 15th 2025
Podcast

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.


Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

ONCOLOGY Staff
July 16th 2022
Article

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.


Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

ONCOLOGY Staff
June 20th 2022
Article

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.